NKG2C/ KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma.
Olaya de DiosM Angeles Ramírez-GonzálezIrene Gómez-SoriaBerta Segura-CollarJuliana ManosalvaDiego MegíasCarlos E De AndreaLeticia Fernández-RubioAurelio Hernández-LaínJuan M Sepúlveda-SánchezMaria E Rodríguez-RuizÁngel Pérez-NúñezDerek A WainwrightRicardo GarginiVicente A TorresPublished in: Journal for immunotherapy of cancer (2024)
expression in shaping the immune profile of GBM and suggests that it is a predictive biomarker for positive responses to immune checkpoint inhibitor treatment in patients with GBM. Future studies could further validate this finding in prospective trials.